{
  "id": 5058,
  "text": "N Engl J Med.2021.Tewari KS1, Sill MW, Long HJ 3rd, et al.Improved survival with bevacizumab in advanced cervical cancer.N Engl J Med 2014 Feb 20;370:734-743.3 Monk BJ, Sill MW, McMeekin DS, et al.Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: N Engl J Med.2021.Tewari KS1, Sill MW, Long HJ 3rd, et al.Improved survival with bevacizumab in advanced cervical cancer.N Engl J Med 2014 Feb 20;370:734-743.3 Monk BJ, Sill MW, McMeekin DS, et al.Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.\n\n<question>: ",
  "ChatGPT_response_0": "是的，这项研究提到了使用贝伐单抗治疗子宫颈癌患者时取得了更好的生存率。根据该研究结果，在晚期子宫颈癌患者中使用贝伐单抗，可以显著提高生存率。这项研究为进一步研究和治疗子宫颈癌提供了重要的临床数据和见解。",
  "query": "这项研究是否提到了使用贝伐单抗治疗子宫颈癌患者时取得了更好的生存率？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 这项研究是否提到了使用贝伐单抗治疗子宫颈癌患者时取得了更好的生存率？\n\n<reference text>: N Engl J Med.2021.Tewari KS1, Sill MW, Long HJ 3rd, et al.Improved survival with bevacizumab in advanced cervical cancer.N Engl J Med 2014 Feb 20;370:734-743.3 Monk BJ, Sill MW, McMeekin DS, et al.Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.\n\n<reply>: ",
  "response": "是的，这项研究提到了使用贝伐单抗治疗子宫颈癌患者时取得了更好的生存率。根据该研究结果，在晚期子宫颈癌患者中使用贝伐单抗，可以显著提高生存率。这项研究为进一步研究和治疗子宫颈癌提供了重要的临床数据和见解。"
}